An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

Inclusion Criteria: * Males aged 18 to 55 years * Body mass index of 18 to 32 kg/m2 and body weight of 55 to 100 kg * Negative result for HIV, HBV, and HCV at Screening * Male subjects with female partners of reproductive potential must be surgically sterile or use adequate birth control * No use of tobacco or nicotine containing products within the past 6 months Exclusion Criteria: * History or presence of any condition or prior surgery that could pose a significant risk in the opinion of the investigator * History of malignancy within the past 5 years * History of any serious allergic reactions or hypersensitivity * Recent history of incomplete bladder emptying with voiding or awakening more than once at a night to void * Usual habit of bowel movements of less than 1 or more than 3 bowel movements per day